[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT03149575 : VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM|
|Ages||Min: 18 Years Max: N/A|
1. Patient must agree to testing of GBM tumor promoter methylation status of the MGMT
gene and tumor (IDH1) gene mutation status. Tissue may be tested at study entry, if
not done previously, or data may be obtained from last known test result for MGMT and
IDH1. IDH1 status may be assessed at study entry, but MGMT status is required prior to
2. Agree to allow the sponsor to collect data on all GBM-related treatments received
after the patient comes off the current study, and to collect survival data after the
patient comes off the current study.
3. Patient must be ? 18 years old.
4. Histologically confirmed initial diagnosis of primary glioblastoma multiforme (GBM) or
gliosarcoma (GS), now recurrent. Patients with recurrent/progressive disease whose
initial diagnostic pathology confirmed GBM or GS will not need re-biopsy. Patients
with prior low-grade glioma or anaplastic glioma are eligible, if histologic
assessment demonstrates transformation to GBM or GS.
5. Patient has previously received standard of care chemo-radiation with temozolomide, ±
adjuvant temozolomide and bevacizumab and now has radiographic evidence of
recurrent/progressive GBM or GS during or after bevacizumab.
6. Patient must have bi dimensionally measurable disease, per the proposed Response
Assessment in NeuroOncology (RANO; Appendix C) (Wen et al., 2010), with measurement of
>1 cm in one diameter and ?5 cm diameter in any plane on MRI performed within 2 weeks
prior to randomization.
7. At least 4 weeks from last chemotherapy or bevacizumab (Avastin®) therapy (6 weeks for
nitrosourea or mitomycin C), or for chemotherapy regimens given continuously or on a
weekly basis with limited potential for delayed toxicity, at least 2 weeks from last
8. If the patient has been using the Optune™ device, it will be discontinued at least
four days prior to commencing treatment with VAL-083, and the patient must have
recovered from all treatment-related toxicities to Grade 1 or less.
9. Baseline MRI must be obtained ? 4 weeks after surgical resection but within 2 weeks
prior to randomization.
10. Adequate recovery from all recent surgery is required; at least 1 week must have
elapsed from the time of a minor surgery; at least 21 days must have elapsed from the
time of a major surgery. Patients must have recovered from all surgery-related
toxicities to Grade 1 or less.
11. Prior therapy with Laser-Induced Thermal Therapy (LITT) is allowed but at least 21
days must have elapsed from last LITT, with recovery from all LITT-related toxicities
to Grade 1 or less and subsequent histologic documentation of recurrence.
12. Greater than 12 weeks from radiotherapy, to minimize the potential for MRI changes
related to radiation necrosis that might be misdiagnosed as pseudoprogression of
disease, unless the recurrence is a new lesion, outside the primary radiation field or
the patient fulfills criteria for early progressive disease by RANO ((Wen et al.,
2010); Appendix C).
13. Prior therapy with gamma knife or other focal high-dose radiation is allowed, but at
least 2 weeks must have elapsed from the time of treatment, and the patient must have
subsequent post-radiotherapy histologic documentation of recurrence in the irradiated
field, unless the recurrence is a new lesion outside the irradiated field.
14. If receiving corticosteroids, patients must be on a stable or decreasing dose of
corticosteroids for ? 5 days prior to baseline MRI.
15. At least 28 days or 5 half-lives (whichever is shorter) since prior investigational
anti-cancer drugs. A minimum of 21 days between termination of the investigational
drug and administration of VAL-083 is required.
16. Must have recovered from all treatment-related toxicities to Grade 1 or less.
17. Patients must have a Karnofsky performance status (KPS; Appendix D) of ? 70%
18. KPS must have been stable during the period from wash-out of prior therapy to
randomization. A declining KPS is defined by reduction of 10 points or more over at
least a 28-day period.
19. Patient must have a predicted life expectancy of at least 12 weeks.
20. Laboratory values as follows at screening and within 7 days of planned first dose of
1. Absolute neutrophil count (ANC) ?1500/?L.
2. Hemoglobin (HgB) ?9 g/dL.
3. Platelets ?100,000/?L (?150,000/?L, if within 12 weeks of prior nitrosourea
4. Serum creatinine ?1.5 x upper limit of normal or creatinine clearance >60 mL/min
(measured or calculated by the Cockcroft-Gault formula) (Cockcroft DW et al,
5. AST, ALT must be <2 x ULN.
6. Total bilirubin <1.5 x the institutional ULN, unless the subject has documented
unconjugated bilirubin disorder such as Gilbert's syndrome.
7. Subjects with known Gilbert's syndrome who have serum bilirubin ? 3 x ULN (NCI
CTCAE v4.03 Grade 2) may be enrolled.
8. International normalized ratio (INR) ? 1.5 and activated partial thromboplastin
time (aPTT) ? 1.5 x the ULN.
9. QTc <450 msec on screening ECG.
21. No clinically significant cardiac conduction disorder on screening.
22. Female patients of child-bearing potential must have a negative serum or urine
pregnancy test within 7 days prior to planned first dose of treatment, and agree to
use dual method of contraception through 90 days after study drug treatment. Approved
methods of contraception include an IUD with spermicide, a female condom with
spermicide, a diaphragm with spermicide, a cervical cap with spermicide, use of a
condom with spermicide by sexual partner or a sterile sexual partner. Women of
childbearing potential are defined to include any female who:
1. Has experienced menarche and has not undergone successful surgical sterilization
(hysterectomy, bilateral tubal ligation, or bilateral oophorectomy); and
2. Is not post-menopausal (defined as amenorrhea >12 consecutive months).
23. If male, patient must be sterile or willing to use an approved method of contraception
from the time of Informed Consent to 90 days after study drug treatment. Males must be
willing to refrain from sperm donation within 90 days after study treatment.
1. Current history of neoplasm other than the entry diagnosis. Exceptions are:
1. Curatively treated basal cell/squamous cell skin cancer
2. Carcinoma in situ of the cervix
3. Patients with previous solid and hematologic tumors, that have been treated with
no evidence of recurrence within the last 5 years, are permitted.
2. Evidence of diffuse subependymal disease or tumor in the brainstem, cerebellum, spinal
cord, or CSF.
3. Radiological evidence of multifocal disease, tumors extending into or crossing the
corpus callosum or leptomeningeal disease.
4. Need for urgent palliative intervention for primary disease (e.g., impending
5. Evidence of recent hemorrhage on baseline MRI of the brain with the following
1. Presence of hemosiderin.
2. Resolving hemorrhagic changes related to surgery.
3. Presence of punctate hemorrhage in the tumor.
6. Concurrent severe, intercurrent illness including, but not limited to unstable
systemic disease, including ongoing or active infection, uncontrolled hypertension,
serious cardiac arrhythmia requiring medication, or psychiatric illness/social
situations that would limit compliance with study requirements.
7. Any of the following cardiac conditions:
1. History of myocardial infarction, acute coronary syndromes (including unstable
angina), coronary angioplasty, and/or stenting up to 12 weeks before Cycle 1, Day
2. Class III or IV heart failure as defined by the New York Heart Association
functional classification system up to 6 months before Cycle 1, Day 1.
8. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or
recent peripheral arterial thrombosis) within 6 months prior to Day 1 of treatment.
9. History of stroke or transient ischemic attack within 6 months prior to beginning
10. Patients receiving prohibited concomitant medications at the start of the study
11. Patients with steroid myopathy.
12. Patients who are HIV positive with an active AIDS-related illness are excluded;
patients who are HIV positive but on stable therapy are not excluded.
13. Patients with a known sensitivity to any of the products to be administered during
treatment and assessments.
14. Women who are pregnant or lactating.
15. Patients unable to undergo an MRI of the brain with contrast.
|Links||Permanent Link to THIS page: http://virtualtrials.com/nct/display1trial.cfm?nct=NCT03149575
| Link to official Clinicaltrials.gov listing
Facility: Kaiser Permanente Los Angeles Medical Center
Richard M Green, M.D.
Richard M Green, M.D. Phone: 323-783-4011
Email not avaialable
Facility: University of California, San Francisco - Division of Neuro-Oncology
Nicholas Butowski, M.D.
Nicholas Butowski, M.D. Phone: 415-353-2966
Email not avaialable
Facility: Atlantic Neuroscience Institute - Brain Tumor Center of NJ
Kurt A Jaeckle, M.D.
Kurt A Jaeckle, M.D. Phone: 908-522-5914
Email not avaialable
Facility: Dent Neurosciences Research Center
Laszlo Mechtler, M.D.
Laszlo Mechtler, M.D. Phone: 716-250-2000
Email not avaialable